Vyome Holdings, Inc

Impetis License Agreement

On May 8, 2026, the Company entered into an Exclusive License Agreement (the “Impetis License Agreement”), dated May 8, 2026, with Impetis Biosciences Limited (A TATA Enterprise, or “Impetis”), pursuant to which the Company was granted an exclusive license to manufacture, commercialize and distribute certain preclinical JAK inhibitor assets (the “Impetis Assets”) worldwide. The Impetis License Agreement provides for consideration of a 1.5% royalty on future net sales, if any, upon commercialization of the Impetis Assets, and no upfront payment obligations, development funding commitments, or milestone payment obligations.

The foregoing description of the Impetis License Agreement is qualified in its entirety by reference to the full text of the Impetis License Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein in its entirety by reference.

Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and Modifications

During the three months ended March 31, 2026, none of our directors or “officers” (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) and Item 408(c) of SEC Regulation S-K, respectively.